Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of HIV Clade C DNA and Protein Vaccine in Healthy Adults
NCT02997969Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2016
- Primary completion
- Jul 2018
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of DNA-HIV-PT123 and bivalent subtype C gp120/MF59 in human immunodeficiency virus infection (HIV) (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency of severe local and systemic reactogenicity signs and symptoms at Month 12, Frequency of adverse events (AEs) at Month 12 and 8 more. Started Jun 2016; status: completed.
02
Drugs
DNA-HIV-PT123bivalent subtype C gp120/MF59
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02997969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02997969.